vs
合众银行（STBA）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是合众银行的1.2倍（$127.1M vs $102.1M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.6%）
合众银行是总部位于美国明尼苏达州明尼阿波利斯、注册地为特拉华州的跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为系统重要性机构。旗下核心运营主体为美国合众银行全国协会，以“U.S. Bank”品牌开展业务，提供银行、投资、抵押贷款等多元金融服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
STBA vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$102.1M
两年增速更快
ZLAB
近两年复合增速
2.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $102.1M | $127.1M |
| 净利润 | $35.1M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 34.4% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | 5.0% | — |
| 每股收益（稀释后） | $0.94 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STBAZLAB
| Q1 26 | $102.1M | — | ||
| Q4 25 | $105.3M | $127.1M | ||
| Q3 25 | $103.0M | $115.4M | ||
| Q2 25 | $100.1M | $109.1M | ||
| Q1 25 | $93.8M | $105.7M | ||
| Q4 24 | $94.3M | $108.5M | ||
| Q3 24 | $96.4M | $101.8M | ||
| Q2 24 | $96.9M | $100.1M |
净利润STBAZLAB
| Q1 26 | $35.1M | — | ||
| Q4 25 | $34.0M | — | ||
| Q3 25 | $35.0M | $-36.0M | ||
| Q2 25 | $31.9M | $-40.7M | ||
| Q1 25 | $33.4M | $-48.4M | ||
| Q4 24 | $33.1M | — | ||
| Q3 24 | $32.6M | $-41.7M | ||
| Q2 24 | $34.4M | $-80.3M |
毛利率STBAZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率STBAZLAB
| Q1 26 | — | — | ||
| Q4 25 | 40.3% | -54.6% | ||
| Q3 25 | 42.6% | -42.3% | ||
| Q2 25 | 40.0% | -50.3% | ||
| Q1 25 | 44.5% | -53.3% | ||
| Q4 24 | 43.8% | -62.6% | ||
| Q3 24 | 43.0% | -66.6% | ||
| Q2 24 | 44.2% | -76.0% |
净利率STBAZLAB
| Q1 26 | 34.4% | — | ||
| Q4 25 | 32.3% | — | ||
| Q3 25 | 33.9% | -31.2% | ||
| Q2 25 | 31.9% | -37.3% | ||
| Q1 25 | 35.6% | -45.8% | ||
| Q4 24 | 35.1% | — | ||
| Q3 24 | 33.8% | -40.9% | ||
| Q2 24 | 35.5% | -80.2% |
每股收益（稀释后）STBAZLAB
| Q1 26 | $0.94 | — | ||
| Q4 25 | $0.88 | $-0.05 | ||
| Q3 25 | $0.91 | $-0.03 | ||
| Q2 25 | $0.83 | $-0.04 | ||
| Q1 25 | $0.87 | $-0.04 | ||
| Q4 24 | $0.86 | $-0.09 | ||
| Q3 24 | $0.85 | $-0.04 | ||
| Q2 24 | $0.89 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $100.8M | — |
| 股东权益账面价值 | $1.4B | $715.5M |
| 总资产 | $9.9B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资STBAZLAB
| Q1 26 | — | — | ||
| Q4 25 | $163.4M | $689.6M | ||
| Q3 25 | $196.2M | $717.2M | ||
| Q2 25 | $203.1M | $732.2M | ||
| Q1 25 | $211.8M | $757.3M | ||
| Q4 24 | $244.8M | $779.7M | ||
| Q3 24 | $228.1M | $616.1M | ||
| Q2 24 | $246.3M | $630.0M |
总债务STBAZLAB
| Q1 26 | $100.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益STBAZLAB
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.5B | $715.5M | ||
| Q3 25 | $1.5B | $759.9M | ||
| Q2 25 | $1.4B | $791.7M | ||
| Q1 25 | $1.4B | $810.8M | ||
| Q4 24 | $1.4B | $840.9M | ||
| Q3 24 | $1.4B | $667.7M | ||
| Q2 24 | $1.3B | $704.2M |
总资产STBAZLAB
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.9B | $1.2B | ||
| Q3 25 | $9.8B | $1.2B | ||
| Q2 25 | $9.8B | $1.2B | ||
| Q1 25 | $9.7B | $1.2B | ||
| Q4 24 | $9.7B | $1.2B | ||
| Q3 24 | $9.6B | $985.3M | ||
| Q2 24 | $9.6B | $987.4M |
负债/权益比STBAZLAB
| Q1 26 | 0.07× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流STBAZLAB
| Q1 26 | — | — | ||
| Q4 25 | $133.6M | $-26.0M | ||
| Q3 25 | $40.5M | $-32.0M | ||
| Q2 25 | $28.3M | $-31.0M | ||
| Q1 25 | $28.7M | $-61.7M | ||
| Q4 24 | $173.4M | $-55.8M | ||
| Q3 24 | $27.6M | $-26.8M | ||
| Q2 24 | $44.7M | $-42.2M |
自由现金流STBAZLAB
| Q1 26 | — | — | ||
| Q4 25 | $128.8M | $-26.7M | ||
| Q3 25 | $39.9M | $-35.0M | ||
| Q2 25 | $27.1M | $-33.9M | ||
| Q1 25 | $27.0M | $-63.2M | ||
| Q4 24 | $170.4M | $-58.4M | ||
| Q3 24 | $26.9M | $-28.2M | ||
| Q2 24 | $43.9M | $-42.9M |
自由现金流率STBAZLAB
| Q1 26 | — | — | ||
| Q4 25 | 122.4% | -21.0% | ||
| Q3 25 | 38.7% | -30.4% | ||
| Q2 25 | 27.1% | -31.1% | ||
| Q1 25 | 28.8% | -59.9% | ||
| Q4 24 | 180.7% | -53.8% | ||
| Q3 24 | 28.0% | -27.7% | ||
| Q2 24 | 45.3% | -42.9% |
资本支出强度STBAZLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 0.5% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 1.8% | 1.5% | ||
| Q4 24 | 3.1% | 2.4% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.9% | 0.7% |
现金转化率STBAZLAB
| Q1 26 | — | — | ||
| Q4 25 | 3.93× | — | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 5.24× | — | ||
| Q3 24 | 0.85× | — | ||
| Q2 24 | 1.30× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
STBA
| Net Interest Income | $88.4M | 87% |
| Noninterest Income | $13.6M | 13% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
